文献速递淋巴瘤

来那度胺/利妥昔单抗的1期研究及来那度胺维持治疗在复发中枢神经系统淋巴瘤中的结局

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
PubMed 文献 · Blood Adv · 2018-01-01

这项1期研究评估了来那度胺单药及联合利妥昔单抗治疗复发中枢神经系统淋巴瘤的安全性、疗效和脑脊液穿透性;在独立队列中评估了挽救治疗后来那度胺维持治疗的疗效。来那度胺可穿透脑室脑脊液,单药有活性;维持治疗可延长缓解持续时间并延迟全脑放疗。

要点

  • 来那度胺在10、15、20 mg剂量水平下可穿透脑室脑脊液,15和20 mg时脑脊液/血浆分配系数≥20%。
  • 9例复发难治性中枢神经系统淋巴瘤患者经来那度胺单药治疗达到优于部分缓解的疗效。
  • 来那度胺维持治疗可延长复发原发性中枢神经系统淋巴瘤完全缓解后的缓解持续时间并延迟全脑放疗。

核心结论

  • 来那度胺可穿透脑室脑脊液,作为单药在复发中枢神经系统淋巴瘤中有活性。
  • 来那度胺维持治疗可增强复发原发性中枢神经系统淋巴瘤挽救治疗后的缓解持续时间,并延迟全脑放疗。

研究设计与样本

  • 1期试验,纳入14例难治性CD20+中枢神经系统淋巴瘤患者,来那度胺剂量水平为10、15和20 mg。
  • 对来那度胺反应不足的患者接受来那度胺联合利妥昔单抗治疗。
  • 独立队列评估复发原发性中枢神经系统淋巴瘤患者经大剂量甲氨蝶呤或局灶照射挽救治疗后接受来那度胺维持治疗的结局。
  • 试验注册号为NCT01542918。

主要发现

  • 9例复发难治性中枢神经系统淋巴瘤患者经来那度胺单药治疗达到优于部分缓解的疗效,其中6例维持缓解≥9个月,4例维持缓解≥18个月。
  • 来那度胺/利妥昔单抗的中位无进展生存期为6个月。
  • 在独立队列中,完全缓解2至5后接受来那度胺维持治疗的缓解持续时间显著长于标准治疗后的缓解持续时间。
  • 来那度胺的脑脊液/血浆分配系数在15和20 mg剂量水平下≥20%。
  • 1个月时脑脊液白细胞介素-10的变化与来那度胺的临床缓解和缓解持续时间相关。

临床怎么用

  • 作者认为来那度胺可穿透脑室脑脊液,作为单药在复发中枢神经系统淋巴瘤中有活性。
  • 作者提供证据表明来那度胺维持治疗可增强复发原发性中枢神经系统淋巴瘤挽救治疗后的缓解持续时间并延迟全脑放疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an unmet need for effective biological therapies for relapsed central nervous system (CNS) lymphoma. Lenalidomide is active in activated B-cell type diffuse large B-cell lymphoma and rituximab is effective in CNS lymphoma. These observations are the basis for this first trial of an immunomodulatory drug as monotherapy in CNS lymphoma, and, in patients with inadequate responses to lenalidomide, with rituximab. In an independent cohort, we evaluated lenalidomide maintenance after salvage with high-dose methotrexate or focal irradiation in relapsed primary CNS lymphoma (PCNSL). We determined safety, efficacy, and cerebrospinal fluid (CSF) penetration of lenalidomide at 10-, 15-, and 20-mg dose levels in 14 patients with refractory CD20+ CNS lymphoma. Nine subjects with relapsed, refractory CNS lymphoma achieved better than partial response with lenalidomide monotherapy, 6 maintained response ≥9 months, and 4 maintained response ≥18 months. Median progression-free survival for lenalidomide/rituximab was 6 months. In the independent cohort, response duration with lenalidomide maintenance after complete responses 2 through 5 were significantly longer than response durations after standard therapy. The CSF/plasma partition coefficient of lenalidomide was ≥20% at 15- and 20-mg dose levels. Change in CSF interleukin-10 at 1 month correlated with clinical response and response duration to lenalidomide. Metabolomic profiling of CSF identified novel biomarkers, including lactate, and implicated indoleamine-2,3 dioxygenase activity with CNS lymphoma progression on lenalidomide. We conclude that lenalidomide penetrates ventricular CSF and is active as monotherapy in relapsed CNS lymphomas. We provide evidence that maintenance lenalidomide potentiates response duration after salvage in relapsed PCNSL and delays whole brain radiotherapy (WBRT). This trial was registered at www.clinicaltrials.gov as #NCT01542918.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018. PMID: 29986852. doi:10.1182/bloodadvances.2017014845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。